SCHEMBL1815259

SCHEMBL1815259

CC(C)(O)CN1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.62
GFER P55789 4/20 0.62
GAA P10253 4/20 0.62
KDM4E B2RXH2 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
RAD52 P43351 2/20 0.62
ALDH1A1 P00352 4/20 0.53
KMT2A Q03164 2/20 0.53
ADRA2C P18825 1/20 0.53
PTK2B Q14289 1/20 0.53
ESR2 Q92731 1/20 0.53
CASP6 P55212 1/20 0.50
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL943610 0.86 MAPT (0.66) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL188931 0.83 MAPT (0.54) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL520529 0.83 ADRA2C (0.57) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL2476191 0.80 CTSL (0.40) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL5725588 0.79 MAPT (0.61) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL8236174 0.78 MAPT (0.55) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL1811762 0.77 SIRT6 (0.59) MAPTSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL13362139 0.77 GAA (0.45) MAPTGAAKDM4ERAD52ALDH1A1
SCHEMBL158007 0.77 MAPT (1.00) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL27805942 0.77 MAPT (0.67) MAPTGFERGAAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2017278-B1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD KK (JP) 2016-11-02 EP disclosed
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD KK (JP) 2014-10-09 US disclosed
US-8791125-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2014-07-29 US disclosed
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES SAGARA TAKESHI 2011-08-04 US disclosed
US-7935708-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2011-05-03 US disclosed
US-7834019-B2 Substituted pyrazolo[3,4-d]pyrimidinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives MERCK SHARP & DOHME LLC 2010-03-11 US disclosed
EP-2017278-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 EP disclosed
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 MAPT 4041/4885GFER 2606/4885GAA 3719/4885
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives WEE1, WEE2, GRK3 MAPT 4041/4885GFER 2606/4885GAA 3719/4885
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives WEE1, WEE2, GRK3 MAPT 4041/4885GFER 2606/4885GAA 3719/4885
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 MAPT 4041/4885GFER 2606/4885GAA 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.